Non-Small Cell Lung Cancer

The accelerated approval was based on a study that evaluated the efficacy in unresectable or metastatic nonsquamous NSCLC.

Previously treated patients with non–small cell lung cancer (NSCLC) saw durable results with andamertinib 240 mg.

Patients 65 years and older had improved overall and cancer-specific survival after undergoing chemoradiotherapy for stage 2 NSCLC.

A white paper explores how biomarker testing enhances patient outcomes and what barriers prevent access in several common cancers.

Eosinophilia serves as a significant biomarker for predicting immune-related adverse events in NSCLC patients treated with immune checkpoint inhibitors.

Experts discuss the urgent need for equitable access to cancer care, addressing barriers in treatment delivery and the importance of personalized medicine.

Experts discuss the intersection of innovation, affordability, and access in cancer care, focusing on multiple myeloma and NSCLC advancements.

Subcutaneous therapy could be the future of non–small cell lung cancer (NSCLC) as it would decrease time needed for treatment.

Comparable overall survival and distant recurrence outcomes make stereotactic body radiation a feasible alternative.

Individuals who had preoperative percutaneous transthoracic needle biopsy (PTNB) had an increased risk of local-regional recurrence in non–small cell lung cancer (NSCLC).

A review found that assessing for health-related quality of life (HRQOL) was not frequently done in studies related to non–small cell lung cancer (NSCLC).

Aumolertinib was compared against osimertinib to demonstrate its efficacy in those with mutated non-small cell lung cancer (NSCLC).

Adverse events related to the immune system tended to accumulate over time when patients used immune checkpoint inhibitors (ICIs) over time.

Amivantamab plus lazertinib enhances survival in NSCLC but requires complex care compared with osimertinib, explained Danny Nguyen, MD, of City of Hope.

Ana Baramidze, MD, head of the Department of Clinical Researches at the Todua Clinic in Tbilisi, Georgia, explained how clinicians can decide how to cemiplimab, which has a low discontinuation rate.

Cemiplimab demonstrated a 56% overall survival rate, making it a potential option for physicians to use for treating non–small cell lung cancer (NSCLC).

The approval allows all patients 12 years and older to use pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection for solid tumor indications approved for intravenous pembrolizumab.

Cemiplimab plus chemotherapy was found to be consistently effective in treating non-small cell lung cancer (NSCLC) and held up in the EMPOWER-Lung 3 trial.

The use of cemiplimab with chemotherapy showed durable improvements in survival outcomes for non-small cell lung cancer (NSCLC) after 5 years.

Cemiplimab shows significant survival benefits over chemotherapy for advanced non–small cell lung cancer (NSCLC) with high PD-L1 expression, enhancing treatment outcomes.

Patients with early-stage non–small cell lung cancer had improved outcomes after surgical treatment if they adhered to quality metrics associated with survival.

Jorge Nieva, MD, explores the challenges of translating biomarker testing into treatment decisions for non–small cell lung cancer (NSCLC), the role of repeat testing in detecting resistance mutations, and the importance of equitable access to molecular diagnostics in value-based care settings.

Precision oncology's promise was the key theme of the July 17 session of the Institute for Value-Based Medicine with faculty from multiple institutions in the Boston, Massachusetts area.

New drugs aren't the only advances in oncology. Innovation includes collaboration between to remove barriers to remove barriers to care, according to experts who gathered for a session of the Institute for Value-Based Medicine in Arlington, Virginia.

Cutting-edge cancer therapies and innovative care models that advance patient access and significantly reduce health care costs took center stage at the Institute of Value-Based Medicine (IVBM) event in Minneapolis, Minnesota.